$14.17
0.110.78%
At Close: -
$13.82
-0.35-2.47%
After Hours: 4:09 PM EDT
15 minutes delayed
Inhibrx Biosciences
INBXNASDAQ
Inhibrx Biosciences (NASDAQ:INBX) Stock, Analyst Ratings, Price Targets, Predictions
Inhibrx Biosciences Inc has a consensus price target of $36.2, established from looking at the 14 latest analyst ratings. The last 3 analyst ratings were released from JMP Securities, JMP Securities, and JMP Securities on November 20, 2023, August 23, 2023, and May 10, 2023. With an average price target of $29.67 between JMP Securities, JMP Securities, and JMP Securities, there's an implied 114.66% upside for Inhibrx Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
JMP Securities
JMP Securities
Credit Suisse
Evercore ISI Group
SMBC Nikko
1calculated from analyst ratings
Analyst Ratings for Inhibrx Biosciences
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/23/2024 | Buy Now | — | JMP Securities | Reni Benjamin | — | Downgrade | Market Outperform → Market Perform | Get Alert |
| 11/20/2023 | Buy Now | 95.37% | JMP Securities | Reni Benjamin | → $27 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 08/23/2023 | Buy Now | 95.37% | JMP Securities | Reni Benjamin | $35 → $27 | Maintains | Outperform | Get Alert |
| 05/10/2023 | Buy Now | 153.26% | JMP Securities | Benjamin Chaiken | → $35 | Reiterates | → Market Outperform | Get Alert |
| 03/08/2023 | Buy Now | 153.26% | JMP Securities | Benjamin Chaiken | $40 → $35 | Maintains | Market Outperform | Get Alert |
| 03/07/2023 | Buy Now | 232.85% | Credit Suisse | Judah Frommer | → $46 | Reiterates | → Outperform | Get Alert |
| 11/08/2022 | Buy Now | 232.85% | Credit Suisse | Judah Frommer | $48 → $46 | Maintains | Outperform | Get Alert |
| 10/05/2022 | Buy Now | 334.15% | Evercore ISI Group | Gavin Clark-Gartner | $54 → $60 | Maintains | Outperform | Get Alert |
| 08/09/2022 | Buy Now | 247.32% | Credit Suisse | Judah Frommer | $53 → $48 | Maintains | Outperform | Get Alert |
| 03/16/2022 | Buy Now | 189.44% | SMBC Nikko | David Dai | → $40 | Initiates | → Outperform | Get Alert |
| 03/02/2022 | Buy Now | 189.44% | JMP Securities | Reni Benjamin | $53 → $40 | Maintains | Market Outperform | Get Alert |
| 11/10/2021 | Buy Now | 283.5% | Credit Suisse | Judah Frommer | — | Maintains | Outperform | Get Alert |
| 11/02/2021 | Buy Now | 283.5% | JMP Securities | Reni Benjamin | — | Maintains | Market Outperform | Get Alert |
| 09/21/2021 | Buy Now | 232.85% | JMP Securities | Reni Benjamin | — | Initiates | → Market Outperform | Get Alert |
FAQ
What is the target price for Inhibrx Biosciences (INBX) stock?
The latest price target for Inhibrx Biosciences (NASDAQ:INBX) was reported by JMP Securities on January 23, 2024. The analyst firm set a price target for $0.00 expecting INBX to fall to within 12 months (a possible -100.00% downside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inhibrx Biosciences (INBX)?
The latest analyst rating for Inhibrx Biosciences (NASDAQ:INBX) was provided by JMP Securities, and Inhibrx Biosciences downgraded their market perform rating.
When was the last upgrade for Inhibrx Biosciences (INBX)?
There is no last upgrade for Inhibrx Biosciences
When was the last downgrade for Inhibrx Biosciences (INBX)?
The last downgrade for Inhibrx Biosciences Inc happened on January 23, 2024 when JMP Securities changed their price target from N/A to N/A for Inhibrx Biosciences Inc.
When is the next analyst rating going to be posted or updated for Inhibrx Biosciences (INBX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inhibrx Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inhibrx Biosciences was filed on January 23, 2024 so you should expect the next rating to be made available sometime around January 23, 2025.
Is the Analyst Rating Inhibrx Biosciences (INBX) correct?
While ratings are subjective and will change, the latest Inhibrx Biosciences (INBX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Inhibrx Biosciences (INBX) is trading at is $13.82, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.